Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
October 16 2024 - 7:01AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene insertion which is necessary for diseases
where a defective gene is remedied by expression of a new DNA
sequence, today announced a poster presentation at the upcoming
European Society of Gene & Cell Therapy (ESGCT) Congress being
held October 22-25, 2024, in Rome, Italy.
Presentation Details:
Title: High-efficiency homology-directed insertion into
the genome using engineered homing endonucleases Poster
Number: #PO678 Presenter: Adam Mischler, PhD, Senior
Scientist, Precision BioSciences Gene Discovery Date and
Time: Thursday, October 24, 2024, 6:00-7:30pm CEST
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS platform is being used to develop in vivo gene editing
therapies for sophisticated gene edits, including gene insertion
(inserting DNA into a gene to cause expression/add function),
elimination (removing a genome, e.g., viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single
AAV).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241016444782/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Jan 2024 to Jan 2025